Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart failure update.

U C Gomes1, J G Cleland

  • 1Cardio.net Editorial Office, Macclesfield, Cheshire, UK. G.M.Porter@medschool.hull.ac.uk

European Journal of Heart Failure
|August 10, 2000
PubMed
Summary
This summary is machine-generated.

The RUSSLAN study found levosimendan safe for post-infarction heart failure patients. This calcium sensitizing agent improved symptoms and survival, offering a unique option among intravenous inotropic treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.

Pharmacological research·2022
Same author

The association between blood groups and COVID-19 infection: a study from the UK Biobank.

Journal of internal medicine·2020
Same author

Tumour biomarkers: association with heart failure outcomes.

Journal of internal medicine·2020
Same author

Added value of frailty and social support in predicting risk of 30-day unplanned re-admission or death for patients with heart failure: An analysis from OPERA-HF.

International journal of cardiology·2018
Same author

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

European heart journal·2018
Same author

Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.

European heart journal·2017
Same journal

A high proportion of children with severe cardiomyopathies show both myocarditis and genetic predispositions.

European journal of heart failure·2026
Same journal

Correction to: Association of patient-centred remote monitoring with clinical outcomes in patients with prior hospitalization: the TELESAT PRIOR-HF study.

European journal of heart failure·2026
Same journal

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same journal

"Reply to Murthy et al. regarding AI-derived LVOT-VTI for monitoring disease progression in transthyretin cardiac amyloidosis".

European journal of heart failure·2026
Same journal

High serum transthyretin concentrations identify a low likelihood of advanced myocardial amyloid burden in suspected ATTR cardiomyopathy.

European journal of heart failure·2026
Same journal

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.

European journal of heart failure·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Post-infarction heart failure requires effective treatments.
  • Intravenous inotropic support is often considered for these patients.

Purpose of the Study:

  • To evaluate the safety and efficacy of levosimendan in patients with post-infarction heart failure.
  • To assess levosimendan's impact on symptoms and survival.

Main Methods:

  • The RUSSLAN study randomized 504 patients.
  • Patients had post-infarction heart failure.
  • Intravenous inotropic support was considered appropriate for participants.

Main Results:

  • Levosimendan was safely administered in the absence of severe hypotension.
  • The agent appeared to improve patient symptoms.

Related Experiment Videos

  • Levosimendan showed potential for improving survival rates.

    • Conclusions:

    • Levosimendan may be a safe and effective treatment for post-infarction heart failure.
    • It offers a potentially unique therapeutic option among intravenous inotropes.